Loading
A Chinese study of about 12,500 people without symptoms that gives them Burning Rock's OverC blood test and follows up positive results.
PREVENT (NCT05227534) is a single-arm interventional study sponsored by Guangzhou Burning Rock Dx Co., Ltd with West China Hospital. It evaluates the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 12,500 participants, a start on 1 June 2022 and primary completion expected on 1 March 2024.
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/